Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156174 | 0.91 | NOS3 (0.32) | — | |
| SCHEMBL3071643 | 0.72 | NOS3 (0.40) | TP53 | |
| SCHEMBL20998266 | 0.67 | SLC7A5 (0.36) | TP53 | |
| SCHEMBL54180 | 0.67 | — | — | |
| SCHEMBL4655641 | 0.67 | — | — | |
| SCHEMBL14102735 | 0.67 | NOS3 (0.36) | — | |
| SCHEMBL29063634 | 0.65 | — | — | |
| SCHEMBL31323093 | 0.65 | TP53 (0.42) | TP53 | |
| SCHEMBL7670285 | 0.63 | — | — | |
| SCHEMBL21283180 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11680192-B2 | Functionalized (co)polymers for adhesive systems | TESA SE (DE) | 2023-06-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-9765022-B2 | Disulfide compounds for delivery of pharmaceutical agents | TUFTS UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170002236-A1 | MULTI-LAYER PRODUCT | TESA SE (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20160082126-A1 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN | UNIV TUFTS (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160009643-A1 | DISULFIDE COMPOUNDS FOR DELIVERY OF PHARMACEUTICAL AGENTS | TRUSTEES OF TUFTS COLLEGE | 2016-01-14 | — | — | US | disclosed |
| US-8945717-B2 | Adhesive material | TESA SE (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20100043969-A1 | METHOD FOR MOUNTING PRINTING PLATES TO PRINTING CYLINDERS OR SLEEVES WITH ADHESIVE TAPE | TESA SE (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20090311473-A1 | HEAT-ACTIVATEDLY BONDABLE 2D DIECUTTING ELEMENT | TESA AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-7459499-B2 | Pressure-sensitive adhesive based on acrylate block copolymers | TESA AG (DE) | 2008-12-02 | — | — | US | disclosed |
| US-7432326-B2 | Pressure-sensitive adhesive based on acrylate block copolymers | TESA AKTIENGESELLSCHAFT (DE) | 2008-10-07 | — | — | US | disclosed |
| US-7410694-B2 | Adhesive | TESA AKTIENGESELLSCHAFT (DE) | 2008-08-12 | — | — | US | disclosed |
| US-7402632-B2 | 2-Component crosslink of end-functionalized polyacrylates | TESA AKTIENGESELLSCHAFT (DE) | 2008-07-22 | — | — | US | disclosed |
| US-20080044611-A1 | Pressure Sensitive Adhesive Tape for the Adhesion of Printing Plates and Method for the Production Thereof | TESA AG (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20070270559-A1 | Functionalised Polymers or Contact Adhesive Masses | TESA SE (DE) | 2007-11-22 | — | — | US | disclosed |
| US-7271203-B2 | Crosslinking of photoiniator-initialized polyacrylates | TESA AKTIENGESELLSCHAFT (DE) | 2007-09-18 | — | — | US | disclosed |
| US-20070172684-A1 | Adhesive material | TESA AG (DE) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | TP53 609/4885 |
| US-20160009643-A1 | DISULFIDE COMPOUNDS FOR DELIVERY OF PHARMACEUTICAL AGENTS | P4HB, PDIA6, PDIA5 | TP53 2453/4885 |
| US-20160082126-A1 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN | SARNP, SAP30BP, SCP2 | TP53 408/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | TP53 609/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | TP53 609/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | TP53 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.